TY - JOUR
T1 - Nanomedicines for advanced cancer treatments
T2 - Transitioning towards responsive systems
AU - van Elk, Merel
AU - Murphy, Bruce P
AU - Eufrásio-da-Silva, Tatiane
AU - O'Reilly, Daniel P
AU - Vermonden, Tina
AU - Hennink, Wim E
AU - Duffy, Garry P
AU - Ruiz-Hernández, Eduardo
N1 - Copyright © 2016 Elsevier B.V. All rights reserved.
PY - 2016/12/30
Y1 - 2016/12/30
N2 - The development of nanomedicines for the treatment of cancer focuses on the local targeted delivery of chemotherapeutic drugs to enhance drug efficacy and reduce adverse effects. The nanomedicines which are currently approved for clinical use are mainly successful in terms of improved bioavailability and tolerability but do not necessarily increase drug performance. Therefore, there is a need for improved drug carrier systems which are able to deliver high doses of anti-cancer drugs to the tumor. Stimuli responsive carriers are promising candidates since drug release can be triggered locally in the tumor via internal (i.e. pH, redox potential, metabolite or enzyme concentration) or external (i.e. heat, ultrasound, light, magnetic field) stimuli. This review summarizes the recent progress in the transition towards stimuli responsive nanomedicines (i.e. liposomes, polymeric micelles, nanogels and mesoporous silica nanoparticles) and other therapy modalities that are currently developed in the fight against cancer like the application of ultrasound, tumor normalization and phototherapy. Furthermore, the potential role of image guided drug delivery in the development of new nanomedicines and its clinical application is discussed.
AB - The development of nanomedicines for the treatment of cancer focuses on the local targeted delivery of chemotherapeutic drugs to enhance drug efficacy and reduce adverse effects. The nanomedicines which are currently approved for clinical use are mainly successful in terms of improved bioavailability and tolerability but do not necessarily increase drug performance. Therefore, there is a need for improved drug carrier systems which are able to deliver high doses of anti-cancer drugs to the tumor. Stimuli responsive carriers are promising candidates since drug release can be triggered locally in the tumor via internal (i.e. pH, redox potential, metabolite or enzyme concentration) or external (i.e. heat, ultrasound, light, magnetic field) stimuli. This review summarizes the recent progress in the transition towards stimuli responsive nanomedicines (i.e. liposomes, polymeric micelles, nanogels and mesoporous silica nanoparticles) and other therapy modalities that are currently developed in the fight against cancer like the application of ultrasound, tumor normalization and phototherapy. Furthermore, the potential role of image guided drug delivery in the development of new nanomedicines and its clinical application is discussed.
KW - Drug delivery
KW - Cancer
KW - Nanomedicine
KW - Stimuli-responsive
KW - Image guided therapies
U2 - 10.1016/j.ijpharm.2016.10.013
DO - 10.1016/j.ijpharm.2016.10.013
M3 - Article
C2 - 27725268
SN - 0378-5173
VL - 515
SP - 132
EP - 164
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
IS - 1-2
ER -
